daridorexant + efavirenz

This is a combination of **daridorexant**, a dual orexin receptor antagonist used for the treatment of insomnia, and **efavirenz**, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the management of HIV infection. Daridorexant acts by selectively and competitively antagonizing the orexin 1 (OX1R) and orexin 2 (OX2R) receptors, inhibiting wake-promoting neuropeptides. Efavirenz blocks HIV-1 reverse transcriptase, an enzyme required for viral replication. There is no established medical use for the combination of these two drugs, but they are sometimes co-administered, leading to significant drug interactions due to efavirenz's modulation of liver enzymes. Efavirenz is a moderate inducer of CYP3A4, reducing plasma concentrations and efficacy of daridorexant when used concomitantly.